BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38366332)

  • 1. Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS Method.
    Posocco B; Zanchetta M; Orleni M; Gagno S; Montico M; Peruzzi E; Roncato R; Gerratana L; Corsetti S; Puglisi F; Toffoli G
    Ther Drug Monit; 2024 Feb; ():. PubMed ID: 38366332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic drug monitoring in breast cancer therapy - LC-MS/MS method for quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, ribociclib, and major metabolites abemaciclib M20 and M2 in human serum.
    Habler K; Kalla AS; Rychlik M; Vogeser M; Teupser D
    J Pharm Biomed Anal; 2023 Feb; 225():115211. PubMed ID: 36603395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "A new LC-MS/MS method for the simultaneous quantification of abemaciclib, its main active metabolites M2 and M20, and letrozole for therapeutic drug monitoring".
    Soledad Poetto A; Posocco B; Zanchetta M; Gagno S; Orleni M; Canil G; Alberti M; Puglisi F; Toffoli G
    J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Sep; 1207():123403. PubMed ID: 35940043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and Validation of a Quantitative LC-MS/MS Method for CDK4/6 Inhibitors Palbociclib, Ribociclib, Abemaciclib, and Abemaciclib-M2 in Human Plasma.
    Burke SM; Kamal M; Goey AKL
    Ther Drug Monit; 2023 Jun; 45(3):327-336. PubMed ID: 36728357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and Validation of a Novel LC-MS/MS Method for the Simultaneous Determination of Abemaciclib, Palbociclib, Ribociclib, Anastrozole, Letrozole, and Fulvestrant in Plasma Samples: A Prerequisite for Personalized Breast Cancer Treatment.
    Turković L; Bočkor L; Ekpenyong O; Silovski T; Lovrić M; Crnković S; Nigović B; Sertić M
    Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer.
    Poetto AS; Posocco B; Gagno S; Orleni M; Zanchetta M; Iacuzzi V; Canil G; Buzzo M; Montico M; Guardascione M; Basile D; Pelizzari G; Alberti M; Gerratana L; Puglisi F; Toffoli G
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Nov; 1185():122985. PubMed ID: 34700133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry.
    Martínez-Chávez A; Rosing H; Hillebrand M; Tibben M; Schinkel AH; Beijnen JH
    Anal Bioanal Chem; 2019 Aug; 411(20):5331-5345. PubMed ID: 31209549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous quantification of abemaciclib and its active metabolites in human and mouse plasma by UHPLC-MS/MS.
    Martínez-Chávez A; Tibben MM; de Jong KAM; Rosing H; Schinkel AH; Beijnen JH
    J Pharm Biomed Anal; 2021 Sep; 203():114225. PubMed ID: 34242947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous determination of LY3214996, abemaciclib, and M2 and M20 metabolites in human plasma, cerebrospinal fluid, and brain tumor by LC-MS/MS.
    Margaryan T; Elliott M; Sanai N; Tovmasyan A
    J Pharm Anal; 2022 Aug; 12(4):601-609. PubMed ID: 36105156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment of an analytical method for simultaneous quantitation of CDK4/6 inhibitors, aromatase inhibitors, and an estrogen receptor antagonist in human plasma using LC-ESI-MS/MS.
    Sato Y; Shigeta K; Hirasawa T; Sato T; Ogura J; Maekawa M; Ebata A; Hamanaka Y; Tada H; Ishida T; Kikuchi M; Mano N
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Mar; 1173():122655. PubMed ID: 33831689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application.
    Posocco B; Buzzo M; Poetto AS; Orleni M; Gagno S; Zanchetta M; Iacuzzi V; Guardascione M; Puglisi F; Basile D; Pelizzari G; Marangon E; Toffoli G
    PLoS One; 2020; 15(2):e0228822. PubMed ID: 32032379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of an LC-MS/MS assay for rapid and simultaneous quantification of 21 kinase inhibitors in human plasma and serum for therapeutic drug monitoring.
    Al Shirity ZN; Westra N; Hateren KV; Munnink THO; Kosterink JGW; Mian P; Hooge MNL; Touw DJ; Gareb B
    J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Sep; 1229():123872. PubMed ID: 37716342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a SPE-LC-MS Method for the Quantitation of Palbociclib and Abemaciclib in Human Plasma.
    Calucică DM; Manda CV; Găman AM; Răileanu Ș; Stanca L; Popescu MDE; Mateescu OG; Biță A; Croitoru O; Neamțu SD
    Molecules; 2022 Dec; 27(23):. PubMed ID: 36500697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimisation of Solid-Phase Extraction and LC-MS/MS Analysis of Six Breast Cancer Drugs in Patient Plasma Samples.
    Turković L; Mutavdžić Pavlović D; Mlinarić Z; Skenderović A; Silovski T; Sertić M
    Pharmaceuticals (Basel); 2023 Oct; 16(10):. PubMed ID: 37895916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A fully validated method for simultaneous determination of icotinib, osimertinib, gefitinib and O-desmethyl gefitinib in human plasma using UPLC-MS/MS for therapeutic drug monitoring.
    Li B; Chen W; Liu F; Wang X; Qin W; Li S; Lu H; Wang G; Liu X; Li P; Zuo X; Zhang X; Liu L; Yang M
    J Pharm Biomed Anal; 2023 Nov; 236():115697. PubMed ID: 37713984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A semi-automated LC-MS/MS method for the determination of LCI699, a steroid 11β-hydroxylase inhibitor, in human plasma.
    Li W; Luo S; Rebello S; Flarakos J; Tse FL
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jun; 960():182-93. PubMed ID: 24814004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and clinical validation of a simple and fast UPLC-ESI-MS/MS method for simultaneous quantification of nine kinase inhibitors and two antiandrogen drugs in human plasma: Interest for their therapeutic drug monitoring.
    Llopis B; Robidou P; Tissot N; Pinna B; Gougis P; Aubart FC; Campedel L; Abbar B; Weil DR; Uzunov M; Gligorov J; Salem JE; Funck-Brentano C; Zahr N
    J Pharm Biomed Anal; 2021 Apr; 197():113968. PubMed ID: 33618135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid Capillary Electrophoresis Method for Simultaneous Determination of Abemaciclib, Ribociclib, and Palbociclib in Pharmaceutical Dosage Forms: A Green Approach.
    Mlinarić Z; Turković L; Begović I; Nigović B; Sertić M
    Molecules; 2022 Nov; 27(21):. PubMed ID: 36364432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Method development and validation for simultaneous determination of six tyrosine kinase inhibitors and two active metabolites in human plasma/serum using UPLC-MS/MS for therapeutic drug monitoring.
    Zhang M; Liu X; Chen Z; Jiang S; Wang L; Tao M; Miao L
    J Pharm Biomed Anal; 2022 Mar; 211():114562. PubMed ID: 35124453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous determination of 11 alkaloids in rat plasma by LC-ESI-MS/MS and a pharmacokinetic study after oral administration of total alkaloids extracted from Naucleaofficinalis.
    Wang G; Wang H; Lin Z; Hou L; Wang JY; Sun L
    J Ethnopharmacol; 2022 Jan; 282():114560. PubMed ID: 34454053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.